XHKG2268
Market cap4.89bUSD
Dec 23, Last price
31.70HKD
1D
-0.94%
1Q
65.45%
IPO
13.21%
Name
WuXi XDC Cayman Inc
Chart & Performance
P/E
125.97
P/S
16.82
EPS
0.24
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
2.12b
+114.44%
Net income
284m
+82.07%
CFO
333m
+32.18%
Earnings
Mar 25, 2025
Profile
WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally. It engages in the discovery, research, development, and manufacture of antibody drug conjugates, bioconjugates, monoclonal antibody intermediates, and payload-linkers associated with bioconjugates. The company was founded in 2013 and is headquartered in Wuxi, China. WuXi XDC Cayman Inc. operates as a subsidiary of WuXi Biologics (Cayman) Inc.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY |
|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | |
| Income | ||||
Revenues | 2,123,839 114.44% | 990,423 218.33% | 311,131 222.91% | |
Cost of revenue | 1,780,334 | 821,161 | 241,338 | |
Unusual Expense (Income) | ||||
NOPBT | 343,505 | 169,262 | 69,793 | |
NOPBT Margin | 16.17% | 17.09% | 22.43% | |
Operating Taxes | 76,074 | 40,070 | 11,923 | |
Tax Rate | 22.15% | 23.67% | 17.08% | |
NOPAT | 267,431 | 129,192 | 57,870 | |
Net income | 283,538 82.07% | 155,731 183.51% | 54,930 108.87% | |
Dividends | ||||
Dividend yield | ||||
Proceeds from repurchase of equity | 3,603,962 | 1,285,462 | ||
BB yield | ||||
| Debt | ||||
Debt current | 1,247 | 75,557 | 24,592 | |
Long-term debt | 4,437 | 7,667 | 2,249 | |
Deferred revenue | ||||
Other long-term liabilities | ||||
Net debt | (4,041,899) | (651,748) | 516 | |
| Cash flow | ||||
Cash from operating activities | 332,845 | 251,816 | 59,136 | |
CAPEX | (529,360) | (387,556) | (51,907) | |
Cash from investing activities | (91,233) | (1,279,543) | (51,587) | |
Cash from financing activities | 3,522,104 | 1,328,213 | 22,343 | |
FCF | (317,603) | (980,033) | 806,955 | |
| Balance | ||||
Cash | 4,047,583 | 734,972 | 26,325 | |
Long term investments | ||||
Excess cash | 3,941,391 | 685,451 | 10,768 | |
Stockholders' equity | 564,052 | 169,518 | 20,134 | |
Invested Capital | 4,893,106 | 1,375,717 | 23,224 | |
ROIC | 8.53% | 18.47% | 28.90% | |
ROCE | 6.29% | 10.95% | 203.04% | |
| EV | ||||
Common stock shares outstanding | 1,077,970 | 1,178,446 | 1,178,446 | |
Price | ||||
Market cap | ||||
EV | ||||
EBITDA | 403,018 | 200,074 | 88,774 | |
EV/EBITDA | ||||
Interest | 742 | 2,916 | 493 | |
Interest/NOPBT | 0.22% | 1.72% | 0.71% | |